These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27065039)

  • 1. Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia.
    Hsiao CJ; Tzai TS; Chen CH; Yang WH; Chen CH
    Dis Markers; 2016; 2016():8915809. PubMed ID: 27065039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
    Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
    Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of molecular species of prostate-specific antigen complexed with immunoglobulin M in prostate cancer and benign prostatic hyperplasia.
    Goč S; Janković M
    Dis Markers; 2013; 35(6):847-55. PubMed ID: 24367138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosylation of prostate specific antigen and its potential diagnostic applications.
    Vermassen T; Speeckaert MM; Lumen N; Rottey S; Delanghe JR
    Clin Chim Acta; 2012 Oct; 413(19-20):1500-5. PubMed ID: 22722018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An In-Depth Glycosylation Assay for Urinary Prostate-Specific Antigen.
    Kammeijer GSM; Nouta J; de la Rosette JJMCH; de Reijke TM; Wuhrer M
    Anal Chem; 2018 Apr; 90(7):4414-4421. PubMed ID: 29502397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved sensitivity and specificity for prostate cancer diagnosis based on the urine PCA3/PSA ratio acquired by sequence‑specific RNA capture.
    Zheng K; Dou Y; He L; Li H; Zhang Z; Chen Y; Ye A; Liu W; Kong L
    Oncol Rep; 2015 Nov; 34(5):2439-44. PubMed ID: 26351770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA.
    Haga Y; Uemura M; Baba S; Inamura K; Takeuchi K; Nonomura N; Ueda K
    Anal Chem; 2019 Feb; 91(3):2247-2254. PubMed ID: 30669833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
    Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
    Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-lectin Affinity Chromatography and Quantitative Proteomic Analysis Reveal Differential Glycoform Levels between Prostate Cancer and Benign Prostatic Hyperplasia Sera.
    Totten SM; Adusumilli R; Kullolli M; Tanimoto C; Brooks JD; Mallick P; Pitteri SJ
    Sci Rep; 2018 Apr; 8(1):6509. PubMed ID: 29695737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of the main PSA glycoforms in aggressive prostate cancer.
    Gratacós-Mulleras A; Duran A; Asadi Shehni A; Ferrer-Batallé M; Ramírez M; Comet J; de Llorens R; Saldova R; Llop E; Peracaula R
    Sci Rep; 2020 Nov; 10(1):18974. PubMed ID: 33149259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The simultaneous detection of free and total prostate antigen in serum samples with high sensitivity and specificity by using the dual-channel surface plasmon resonance.
    Jiang Z; Qin Y; Peng Z; Chen S; Chen S; Deng C; Xiang J
    Biosens Bioelectron; 2014 Dec; 62():268-73. PubMed ID: 25016334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.
    Llop E; Ferrer-Batallé M; Barrabés S; Guerrero PE; Ramírez M; Saldova R; Rudd PM; Aleixandre RN; Comet J; de Llorens R; Peracaula R
    Theranostics; 2016; 6(8):1190-204. PubMed ID: 27279911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The kallikrein family of proteins as urinary biomarkers for the detection of prostate cancer.
    Sardana G; Diamandis EP
    Clin Biochem; 2009 Sep; 42(13-14):1483-6. PubMed ID: 19560453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.
    Janković MM; Kosanović MM
    Clin Biochem; 2005 Jan; 38(1):58-65. PubMed ID: 15607318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.